Comparison of efficacy and safety of preoperative Chemoradiotherapy in locally advanced upper and middle/lower rectal cancer

Table 4 Prognostic factors analysis for neoadjuvant chemoradiation responder

Characteristics			No responder		Responder		Univariate	Multivariate
	Total		TRG2 + TRG3^a		TRG0 + TRG1^a		P-value	P-value	OR	95%CI
	N	(%)	n = 76	(%)	n = 97	(%)
Age
< 65	109	63	50	65.8	59	60.8	0.502	0.439	0.77	0.397–1.493
> = 65	64	37	26	34.2	38	39.2
Gender
Male	115	66.5	54	71.1	61	62.9	0.259	0.223	0.653	0.329–1.297
Female	58	37.1	22	28.9	36	37.1
RT^b technique
3DCRT^c	44	25.4	21	27.6	23	23.7	0.557	0.934	1.031	0.496–2.145
IG-IMRT^d	129	74.6	55	72.4	74	76.3
Location (rectum)
Middle/Lower	115	66.5	56	73.7	59	60.8	0.075	0.087	1.847	0.915–3.725
Upper	58	33.5	20	26.3	38	39.2
Clinical tumor depth
T4	25	14.5	11	14.5	14	14.4	0.994	0.292	1.676	0.642–4.376
T2–3	148	85.5	65	85.5	83	85.6
Clinical lymph node metastasis
N1–2	145	83.8	66	86.8	79	81.4	0.339	0.137	1.972	0.805–4.832
N0	28	16.2	10	13.2	18	18.6
Concurrent chemotherapy
Fluoropyrimidine	94	54.3	50	65.8	44	45.4	0.007	0.004	2.604	1.346–5.038
FOLFOX	79	45.7	26	34.2	53	54.6

^aTumor regression grade; ^bradiotherapy; ^cthree-dimensional conventional radiotherapy; ^dimage guided intensity modulated radiotherapy

ISSN: 1748-717X